Medigen to hold small Phase 3 trial of its COVID-19 vaccine in Paraguay

Medigen Vaccine Biologics Corp. announced Tuesday that it has received permission to hold a 1,000-person Phase 3 clinical trial in Paraguay for its COVID-19 vaccine, which was granted emergency use authorization (EUA) in Taiwan the day before.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)